GlassScriptPhysician profile
Bernadette Herrera
NPI 1508156084
$5,809.05
in general payments reported to CMS, 2019-2025
46 companies · $5,200 in 2025
The $5,200 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $157 · 2023: $117 · 2024: $196 · 2025: $5,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,486 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,486.48 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $371.86 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $314.24 | 2025 | Ultomiris |
| Ucb, INC. | $308.58 | 2025 | Fintepla, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $304.86 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $284.04 | 2025 | |
| Harmony Biosciences LLC | $267.82 | 2025 | |
| Sk Life Science, INC. | $257.19 | 2025 | Xcopri |
| Neurocrine Biosciences, INC. | $245.09 | 2025 | |
| Lilly USA, LLC | $237.85 | 2025 | Kisunla, Zepbound |
| Neurelis, INC. | $209.83 | 2025 | Valtoco |
| Janssen Pharmaceuticals, INC | $198.35 | 2022-2025 | Spravato |
| Lundbeck LLC | $192.33 | 2025 | Vyepti, Rexulti |
| Janssen Biotech, INC. | $191.33 | 2025 | |
| Acadia Pharmaceuticals INC | $175.73 | 2025 | Nuplazid |
| Emd Serono, INC. | $171.51 | 2025 | Mavenclad |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $171.41 | 2022-2025 | |
| Argenx US, INC. | $166.62 | 2025 | Vyvgart Hytrulo |
| Genzyme Corporation | $154.92 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $142.57 | 2025 | Crexont, Ongentys |
| Genentech, INC. | $128.29 | 2025 | Ocrevus |
| Ani Pharmaceuticals, INC. | $125.01 | 2025 | Purified Cortrophin Gel |
| Tg Therapeutics, INC. | $124.99 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $120.38 | 2021-2024 | Fasenra, Breztri, Tezspire |
| E.R. Squibb & Sons, L.L.C. | $102.96 | 2021-2022 | |
| Genentech USA, INC. | $101.20 | 2025 | Ocrevus Zunovo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $88.56 | 2025 | Rexulti |
| Cvrx, INC. | $85.74 | 2025 | Barostim Neo System |
| Axsome Therapeutics, INC. | $68.75 | 2025 | Sunosi |
| Glaxosmithkline, LLC. | $56.86 | 2024-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $55.87 | 2023-2024 | Dupixent |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.40 | 2025 | Caplyta |
| Insmed, INC. | $42.46 | 2023-2024 | Arikayce |
| Biogen, INC. | $37.87 | 2025 | Vumerity |
| Medtronic, INC. | $27.00 | 2025 | Percept PC Brainsense |
| Ipsen Biopharmaceuticals, INC | $26.66 | 2025 | Dysport |
| Avadel Cns Pharmaceuticals, LLC | $23.49 | 2025 | Lumryz |
| Ge Healthcare | $21.93 | 2025 | |
| Merz Pharmaceuticals, LLC | $20.65 | 2025 | Xeomin |
| Amgen INC. | $19.64 | 2025 | Uplizna |
| Octapharma USA, INC. | $19.34 | 2025 | Panzyga |
| Baxter Healthcare | $18.48 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Vanda Pharmaceuticals INC. | $17.94 | 2025 | Ponvory |
| Otsuka America Pharmaceutical, INC. | $17.87 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $17.10 | 2025 | Austedo Xr |
| Electromed, INC. | $14.54 | 2023 | Smartvest |
| Philips North America LLC | $13.94 | 2024 | (Ak6) Vest Therapy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernadette Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.